



Oral Presentation on Antengene's Anti-CD24 Monoclonal Antibody ATG-031 Selected for SITC's Top 100 Abstracts

Antengene is proud to announce that the oral presentation for ATG-031 (anti-CD24 monoclonal antibody) presented at **the 37th Society for Immunotherapy of Cancer Annual Meeting (SITC 2022)** was selected for **the SITC top 100 abstracts.**

ATG-031 is a first-in-class, humanized anti-CD24 antibody. ATG-031 potently binds to CD24-positive tumor cells. ATG-031 blocks the interaction between CD24 and Siglec-10 and induces potent macrophage-dependent tumor cell phagocytosis. The Company intends to **file an investigational new drug (IND) for ATG-031 in H1:2023.**

About Antengene

Antengene Corporation Limited (**"Antengene"** , SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, driven by its vision of **"Treating Patients Beyond Borders"** .



Since its founding in 2017, Antengene has built a broad and expanding pipeline of 15 clinical and preclinical assets, including 10 assets with global rights and 5 with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 26 investigational new drug (IND) approvals in Asia and the U.S., and submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in mainland China, Taiwan, China, South Korea, Singapore and Australia.